Koch Industries Inc. decreased its holdings in shares of Insulet Co. (NASDAQ:PODD) by 25.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,247 shares of the medical instruments supplier’s stock after selling 1,478 shares during the quarter. Koch Industries Inc.’s holdings in Insulet were worth $293,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. Schwab Charles Investment Management Inc. grew its position in shares of Insulet by 4.1% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 276,930 shares of the medical instruments supplier’s stock worth $19,109,000 after buying an additional 10,989 shares during the period. Bank of New York Mellon Corp grew its position in shares of Insulet by 6.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 289,027 shares of the medical instruments supplier’s stock worth $15,919,000 after buying an additional 18,111 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Insulet during the 3rd quarter worth approximately $33,373,000. Swiss National Bank grew its position in shares of Insulet by 2.9% during the 4th quarter. Swiss National Bank now owns 98,900 shares of the medical instruments supplier’s stock worth $6,824,000 after buying an additional 2,800 shares during the period. Finally, New York State Common Retirement Fund grew its position in shares of Insulet by 14.0% during the 3rd quarter. New York State Common Retirement Fund now owns 71,585 shares of the medical instruments supplier’s stock worth $3,943,000 after buying an additional 8,785 shares during the period.
Shares of PODD opened at $83.77 on Friday. The company has a debt-to-equity ratio of 3.57, a quick ratio of 5.85 and a current ratio of 6.24. Insulet Co. has a twelve month low of $38.43 and a twelve month high of $88.88. The company has a market capitalization of $4,928.79, a price-to-earnings ratio of -182.11 and a beta of 1.38.
Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.04). Insulet had a negative net margin of 5.79% and a negative return on equity of 29.73%. The company had revenue of $130.50 million during the quarter, compared to the consensus estimate of $125.16 million. During the same period in the previous year, the firm posted ($0.16) EPS. The business’s quarterly revenue was up 26.0% compared to the same quarter last year. analysts anticipate that Insulet Co. will post -0.29 earnings per share for the current year.
In other news, EVP Bradley A. Thomas sold 7,250 shares of Insulet stock in a transaction that occurred on Wednesday, March 14th. The shares were sold at an average price of $83.81, for a total value of $607,622.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director David A. Lemoine sold 641 shares of Insulet stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $76.81, for a total transaction of $49,235.21. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,800 shares of company stock worth $2,412,739. Insiders own 1.90% of the company’s stock.
Several equities research analysts have recently commented on PODD shares. BidaskClub upgraded shares of Insulet from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 23rd. Oppenheimer set a $82.00 price target on shares of Insulet and gave the stock a “hold” rating in a research report on Thursday, February 22nd. Barclays reissued a “buy” rating and set a $78.00 price objective on shares of Insulet in a research note on Wednesday, December 13th. UBS raised shares of Insulet from a “market perform” rating to an “outperform” rating in a research note on Monday, January 8th. Finally, Zacks Investment Research lowered shares of Insulet from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Seven research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $75.00.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/koch-industries-inc-decreases-holdings-in-insulet-co-podd.html.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.